EBOS Group Limited (EBOSY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
EBOS Group Limited (EBOSY) with AI Score 42/100 (Weak). EBOS Group Limited is a diversified healthcare and animal care company operating in Australia, Southeast Asia, and New Zealand. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026EBOS Group Limited (EBOSY) Healthcare & Pipeline Overview
EBOS Group Limited is a diversified healthcare and animal care products distributor in Australia, Southeast Asia, and New Zealand. With a wide range of products and services, EBOS operates through its Healthcare and Animal Care segments, providing healthcare logistics, medication management, and veterinary products, distinguishing itself through its integrated retail programs and extensive distribution network.
Investment Thesis
EBOS Group Limited presents a compelling investment case based on its diversified revenue streams and stable market position in the healthcare and animal care sectors. With a P/E ratio of 11.20 and a dividend yield of 7.05%, EBOS offers potential value and income. The company's growth is underpinned by its expansion in Southeast Asia and its established presence in Australia and New Zealand. Catalysts include ongoing expansion of its healthcare logistics and animal care product lines. Potential risks include regulatory changes in the healthcare sector and currency fluctuations affecting its international operations. The company's beta of 0.18 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $1.67 billion, reflecting its established position in the healthcare and animal care sectors.
- P/E ratio of 11.20, indicating a potentially undervalued investment relative to its earnings.
- Dividend yield of 7.05%, offering a substantial income stream for investors.
- Gross margin of 7.2%, reflecting the company's ability to manage its cost of goods sold.
- Beta of 0.18, suggesting lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Diversified revenue streams across healthcare and animal care.
- Established distribution network in Australia, Southeast Asia, and New Zealand.
- Integrated retail programs for independent pharmacies.
- Strong relationships with suppliers and customers.
Weaknesses
- Relatively low gross margin compared to industry peers.
- Exposure to regulatory changes in the healthcare sector.
- Dependence on key suppliers and customers.
- Limited brand recognition outside of core markets.
Catalysts
- Ongoing: Expansion of healthcare logistics and distribution services in Southeast Asia.
- Ongoing: Increased demand for animal care products driven by pet humanization trends.
- Upcoming: Potential strategic acquisitions to expand product portfolio and geographic reach.
- Ongoing: Development of innovative healthcare solutions, such as medication management software.
- Ongoing: Growth in the vitamins, minerals, and supplements market.
Risks
- Potential: Regulatory changes in the healthcare sector impacting product approvals and pricing.
- Potential: Economic downturns affecting consumer spending on healthcare and pet products.
- Ongoing: Currency fluctuations impacting international operations.
- Potential: Disruptions in the supply chain due to geopolitical events or natural disasters.
- Potential: Intense competition from established players in the healthcare and animal care industries.
Growth Opportunities
- Expansion in Southeast Asia: EBOS has the opportunity to expand its presence in the growing Southeast Asian healthcare and animal care markets. The increasing demand for healthcare services and pet products in countries like Indonesia, Thailand, and Vietnam presents a significant growth opportunity. EBOS can leverage its existing distribution network and product portfolio to capture a larger market share. This expansion is expected to contribute to revenue growth over the next 3-5 years.
- Increased Demand for Animal Care Products: The pet industry is experiencing significant growth, driven by the increasing humanization of pets and a greater focus on pet health and wellness. EBOS can capitalize on this trend by expanding its range of pet nutrition, treats, and grooming products. The company can also leverage its veterinary product distribution network to reach a wider customer base. This growth opportunity is expected to drive revenue growth in the animal care segment over the next 2-3 years.
- Healthcare Logistics and Distribution: EBOS can further strengthen its position in healthcare logistics and distribution by expanding its warehousing and clinical trial management services. The increasing complexity of healthcare supply chains and the growing demand for clinical trials present a significant opportunity. EBOS can leverage its expertise and infrastructure to provide efficient and reliable logistics solutions to healthcare providers and pharmaceutical companies. This expansion is expected to contribute to revenue growth over the next 3-5 years.
- Strategic Acquisitions: EBOS can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring companies in complementary sectors, such as specialty pharmaceuticals or veterinary services, can enhance EBOS's competitive position and drive revenue growth. The company can also target acquisitions in new geographic markets to expand its presence and diversify its revenue streams. These acquisitions are expected to contribute to revenue growth over the next 3-5 years.
- Development of Innovative Healthcare Solutions: EBOS can invest in the development of innovative healthcare solutions, such as medication management software and telehealth services. The increasing adoption of digital health technologies presents a significant opportunity. EBOS can leverage its expertise and infrastructure to develop solutions that improve patient outcomes and streamline healthcare delivery. This development is expected to contribute to revenue growth over the next 3-5 years.
Opportunities
- Expansion in Southeast Asia and other emerging markets.
- Increased demand for animal care products.
- Strategic acquisitions to expand product portfolio and geographic reach.
- Development of innovative healthcare solutions.
Threats
- Intense competition from established players in the healthcare and animal care industries.
- Economic downturns affecting consumer spending on healthcare and pet products.
- Currency fluctuations impacting international operations.
- Disruptions in the supply chain due to geopolitical events or natural disasters.
Competitive Advantages
- Extensive distribution network across Australia, Southeast Asia, and New Zealand.
- Diversified product portfolio across healthcare and animal care sectors.
- Integrated retail programs for independent pharmacies.
- Long-standing relationships with suppliers and customers.
About EBOSY
EBOS Group Limited, originally founded in 1922 as Early Bros Dental & Surgical Supplies Ltd., has evolved into a diversified healthcare and animal care company. Headquartered in Docklands, Australia, EBOS operates across Australia, Southeast Asia, and New Zealand. The company's two main segments are Healthcare and Animal Care. The Healthcare segment provides healthcare logistics, medication management solutions, pharmacy management software, and a range of services including business intelligence and health communications. It also offers community-based healthcare services, vitamins, supplements, and functional foods. EBOS provides integrated retail programs for independent pharmacies, such as Pharmacy Choice and healthSAVE. The company supplies health and wellness products to hospitals, aged care facilities, and specialist clinics. The Animal Care segment provides pet nutrition, treats, grooming products, and veterinary products for companion and production animals. EBOS distributes allografts solutions, aesthetic healthcare devices, medical-grade cosmeceuticals, injectables, surgical devices, and medical consumables. The company changed its name to EBOS Group Limited in 1986, reflecting its expanded scope and strategic direction.
What They Do
- Markets, wholesales, and distributes healthcare products.
- Markets, wholesales, and distributes medical products.
- Markets, wholesales, and distributes pharmaceutical products.
- Markets, wholesales, and distributes animal care products.
- Provides healthcare logistics and medication management solutions.
- Offers pharmacy management software and business intelligence services.
- Supplies health and wellness products to hospitals and aged care facilities.
Business Model
- Distribution of healthcare, medical, pharmaceutical, and animal care products to various customers.
- Provision of healthcare logistics and medication management solutions.
- Sales of vitamins, minerals, supplements, and functional foods.
- Wholesaling of veterinary products for companion and production animals.
Industry Context
EBOS Group Limited operates in the healthcare and animal care industries, which are experiencing steady growth driven by aging populations and increasing pet ownership. The healthcare sector is characterized by stringent regulations and high barriers to entry. EBOS competes with companies like ARSUF, DRWKF, EKTAF, IUSDF, and MEDGF, focusing on distribution and specialized services. The animal care industry is driven by pet humanization trends, with increasing demand for premium pet products and veterinary services. EBOS is positioned to benefit from these trends through its established distribution network and diversified product offerings.
Key Customers
- Public and private hospitals
- Day surgeries and general practices
- Aged care facilities
- Specialist clinics
- Veterinary clinics
Financials
Chart & Info
EBOS Group Limited (EBOSY) stock price: Price data unavailable
Latest News
-
Ebos Group Ltd (ASX:EBO) Half Year 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Yahoo! Finance: EBOSY News · Feb 25, 2026
-
EBOS Group Limited (EBOSF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Feb 24, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EBOSY.
Price Targets
Wall Street price target analysis for EBOSY.
MoonshotScore
What does this score mean?
The MoonshotScore rates EBOSY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Adam Luke Hall
CEO
Adam Luke Hall is the CEO of EBOS Group Limited, managing a workforce of 5200 employees. His background includes extensive experience in the healthcare and pharmaceutical industries. Hall has held various leadership positions in multinational corporations, focusing on strategic planning, operational efficiency, and business development. He has a proven track record of driving growth and improving profitability. Hall's expertise spans across supply chain management, regulatory affairs, and market expansion.
Track Record: Under Adam Luke Hall's leadership, EBOS Group Limited has expanded its presence in Southeast Asia and strengthened its position in the Australian and New Zealand markets. He has overseen strategic acquisitions and partnerships that have enhanced the company's product portfolio and geographic reach. Hall has also focused on improving operational efficiency and implementing innovative healthcare solutions. His tenure has been marked by consistent revenue growth and improved profitability.
EBOS Group Limited ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. EBOSY functions as a Level 1 ADR, meaning it trades over-the-counter (OTC) without needing to meet the stringent listing requirements of exchanges like the NYSE or NASDAQ. This allows U.S. investors to invest in EBOS Group Limited more easily.
- Home Market Ticker: EBOS trades on the Australian Securities Exchange (ASX) under the ticker EBOS.
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: EBOS
EBOSY OTC Market Information
EBOSY trades on the OTC Other tier, which represents the lowest tier of the OTC market. Companies on this tier may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. This tier is generally associated with higher risk and less transparency compared to stocks listed on major exchanges like the NYSE or NASDAQ. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity and potential for price volatility.
- Lack of transparency and limited financial disclosure.
- Higher risk of fraud or manipulation compared to stocks listed on major exchanges.
- Potential for delisting or suspension of trading.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Check for any regulatory actions or legal proceedings against the company.
- Monitor the company's news and press releases for any material developments.
- Consult with a financial advisor before making any investment decisions.
- EBOS Group Limited is an established company with a long operating history.
- The company has a diversified revenue stream across healthcare and animal care sectors.
- EBOS Group Limited is listed on the Australian Securities Exchange (ASX).
- The company has a market capitalization of $1.67 billion.
- EBOS Group Limited has a dividend yield of 7.05%.
EBOSY Healthcare Stock FAQ
What does EBOS Group Limited do?
EBOS Group Limited is a diversified healthcare and animal care company operating in Australia, Southeast Asia, and New Zealand. The company's Healthcare segment provides healthcare logistics, medication management solutions, pharmacy management software, and a range of services including business intelligence and health communications. The Animal Care segment provides pet nutrition, treats, grooming products, and veterinary products for companion and production animals. EBOS distributes its products to hospitals, aged care facilities, specialist clinics, and veterinary clinics.
What do analysts say about EBOSY stock?
AI analysis is pending for EBOSY stock. Generally, analysts consider factors such as the company's diversified revenue streams, market position in the healthcare and animal care sectors, and growth opportunities in Southeast Asia. Key valuation metrics include the P/E ratio, dividend yield, and gross margin. Growth considerations include the company's ability to expand its product portfolio and geographic reach. However, regulatory risks and currency fluctuations are also considered.
What are the main risks for EBOSY?
The main risks for EBOSY include regulatory changes in the healthcare sector, which could impact product approvals and pricing. Economic downturns could affect consumer spending on healthcare and pet products. Currency fluctuations could impact international operations, particularly in Southeast Asia. Disruptions in the supply chain due to geopolitical events or natural disasters could also pose a risk. Intense competition from established players in the healthcare and animal care industries is another factor to consider.
What are the key factors to evaluate for EBOSY?
EBOS Group Limited (EBOSY) currently holds an AI score of 42/100, indicating low score. Key strength: Diversified revenue streams across healthcare and animal care.. Primary risk to monitor: Potential: Regulatory changes in the healthcare sector impacting product approvals and pricing.. This is not financial advice.
How frequently does EBOSY data refresh on this page?
EBOSY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven EBOSY's recent stock price performance?
Recent price movement in EBOS Group Limited (EBOSY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified revenue streams across healthcare and animal care.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider EBOSY overvalued or undervalued right now?
Determining whether EBOS Group Limited (EBOSY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying EBOSY?
Before investing in EBOS Group Limited (EBOSY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for EBOSY. Analyst consensus and valuation metrics are based on historical data and industry averages.
- Risk factors are based on general industry trends and company-specific information.